PharmiWeb.com - Global Pharma News & Resources
05-Nov-2024

PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer

PharmaSGP Holding SE / Key word(s): Personnel
PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer

05-Nov-2024 / 10:02 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer

Gräfelfing, November 05, 2024 – Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will take over the position of Chief Executive Officer (CEO) of the company on January 1, 2025. This was decided by the Supervisory Board today. Peter Gerckens succeeds Natalie Weigand in this position. She informed the Supervisory Board today that she has decided not to extend her contract, which expires at the end of the year. However, Natalie Weigand will remain associated with the company in an advisory role after her departure.

*    *    *
 

Contact

PharmaSGP Holding SE
Claudius Krause | Jakob Hafer (cometis AG)
Lochhamer Schlag 1
82166 Gräfelfing | Germany
Phone: +49 611 205855-0
E-Mail: ir@pharmasgp.com



End of Inside Information

05-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: PharmaSGP Holding SE
Lochhamer Schlag 1
82166 Gräfelfing
Germany
E-mail: ir@pharmasgp.com
Internet: https://pharmasgp.com
ISIN: DE000A2P4LJ5
WKN: A2P4LJ
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Tradegate Exchange
EQS News ID: 2022283

 
End of Announcement EQS News Service

Editor Details

Last Updated: 05-Nov-2024